ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2015-05-14

Name: ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2015-05-14
Creator: ELOXX PHARMACEUTICALS, INC.

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-05-14 (fiscal Q3 2015): 25 published measures, 70 facts as tagged in accession 0001144204-15-030595.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-05-14
Fiscal period: fiscal Q3 2015
Accession: 0001144204-15-030595 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-03-31	16,919,756	USD
At 2014-06-30	33,334,828	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-03-31	5,713,763	USD
At 2014-06-30	5,844,898	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-03-31	11,205,993	USD
At 2014-06-30	27,489,930	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-03-31	469,980	USD
At 2014-06-30	6,111,340	USD
At 2014-03-31	6,198,027	USD
At 2013-06-30	1,602,294	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	-1,227,075	USD	90
2014-07-01 to 2015-03-31	-17,157,006	USD	274
2014-01-01 to 2014-03-31	-2,146,754	USD	90
2013-07-01 to 2014-03-31	-5,550,725	USD	274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-07-01 to 2015-03-31	117,258	USD	274
2013-07-01 to 2014-03-31	0	USD	274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-03-31	226,753	USD
At 2014-06-30	223,475	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	498,402	USD	90
2014-07-01 to 2015-03-31	877,573	USD	274
2014-01-01 to 2014-03-31	268,720	USD	90
2013-07-01 to 2014-03-31	735,977	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	-1,224,995	USD	90
2014-07-01 to 2015-03-31	-17,157,709	USD	274
2014-01-01 to 2014-03-31	-2,128,943	USD	90
2013-07-01 to 2014-03-31	-5,470,579	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-03-31	598,147	USD
At 2014-06-30	7,224,398	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-03-31	1,655,519	USD
At 2014-06-30	1,825,170	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-03-31	656,470	USD
At 2014-06-30	901,180	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit
At 2015-03-31	5,780,951	USD
At 2014-12-31	13,902,917	USD
At 2014-06-30	13,902,917	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit
At 2015-03-31	463,135	USD
At 2014-12-31	283,393	USD
At 2014-06-30	2,178,867	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	235,255	USD	90
2014-07-01 to 2015-03-31	3,727,341	USD	274
2014-01-01 to 2014-03-31	966,344	USD	90
2013-07-01 to 2014-03-31	2,508,098	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-03-31	13,975,140	shares
At 2014-06-30	13,846,361	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2015-03-31	116,545,088	USD
At 2014-06-30	115,631,726	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2015-03-31	138,244	USD
At 2014-06-30	99,728	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2015-03-31	825,815	USD
At 2014-06-30	923,990	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2015-03-31	128,167	USD
At 2014-06-30	1,113,058	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	-1,236,431	USD	90
2014-07-01 to 2015-03-31	-17,198,584	USD	274
2014-01-01 to 2014-03-31	-5,024,265	USD	90
2013-07-01 to 2014-03-31	-8,470,476	USD	274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	-1,236,431	USD	90
2014-07-01 to 2015-03-31	-17,198,584	USD	274
2014-01-01 to 2014-03-31	-5,024,265	USD	90
2013-07-01 to 2014-03-31	-8,470,476	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	1,027,240	USD	90
2014-07-01 to 2015-03-31	3,055,066	USD	274
2014-01-01 to 2014-03-31	1,162,599	USD	90
2013-07-01 to 2014-03-31	2,877,320	USD	274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2015-01-01 to 2015-03-31	0	USD	90
2014-07-01 to 2015-03-31	24,977	USD	274
2014-01-01 to 2014-03-31	85,161	USD	90
2013-07-01 to 2014-03-31	237,341	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-07-01 to 2015-03-31	-249,212	USD	274
2013-07-01 to 2014-03-31	-312,384	USD	274

Inspect the source

Entity: ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured: 2026-09-20T05:15:09.498Z
SEC response SHA-256: b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))